A study of GDC-0449 before surgery for pancreatic cancer (HIPPoS)

Cancer type:

Pancreatic cancer

Status:

Results

Phase:

Phase 2

This study looked at having a drug called GDC-0449 before surgery to remove cancer of the pancreas. It was for people who have the most common type of pancreatic cancer called adenocarcinoma.

More about this trial

If pancreatic cancer is diagnosed at an early stage, it may be possible to have surgery to remove it. This studywas for people having surgery called a Whipple’s operation or a distal pancreatectomy.

Researchers were trying to find out more about a new drug called GDC-0449. We know from laboratory research that it can block a type of chemical signalling between cells which may affect the growth of pancreatic cancer. 

The aims of the study were to

  • See the effect GDC-0449 has on pancreatic cancer and the surrounding healthy tissue
  • Learn more about the side effects

Summary of results

This study closed early due to a lack of patients. 

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor D Tuveson

Supported by

Cambridge University Hospitals NHS Foundation Trust
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
Roche-Genentech

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 7994

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think